Loading MED company information
Open the financials tab to load SEC data
Loading MED data
Loading MED data
Loading MED data
Loading MED data
Loading MED data
Few overheating or already-surging signals — relatively calm. A good stage to observe pre-breakout conditions patiently.
Some risk factors present — volatility, short-term overheating, or thin liquidity. Size and scale in carefully if entering.
Already surged, RSI overheated, extended far from highs, or earnings imminent. Chasing now carries meaningful pullback risk.
MED's RSI(14) currently reads 50. RSI is a momentum indicator that reflects how often and how sharply a stock has been rising lately. Readings above 70 are typically read as overbought and below 30 as oversold — this one falls in the 'normal' range. Treat this as one data point on MED, not a standalone signal. → Learn more
ADX currently reads 15. ADX is a strength-only gauge: it rises when a move is sustained, regardless of which way it points (25+ is considered pronounced). Right now MED shows +DI sits above -DI, favoring the upside, putting it in the 'weak trend' range on ADX. Cross-check this against MED's other indicators above before drawing a conclusion. → Learn more
MED's Bollinger Band width is in the bottom 13% (narrow) of its past year, and the squeeze indicator is currently active. This measures how tight the recent trading range is relative to where it normally sits. A squeeze is often followed by a volatility expansion in either direction. As with any single metric, weigh this alongside MED's full indicator set. → Learn more
MED's OBV is currently not showing a clear rise (none), and the up/down volume ratio is 1.2x. OBV tracks whether volume is piling up on up days or down days over time. Treat this as one data point on MED, not a standalone signal. → Learn more
MED's recent volume is running at 1.0x its usual level. This ratio shows how many times normal volume the stock has been trading at lately — a reference point for whether order flow is concentrating around this stock. Cross-check this against MED's other indicators above before drawing a conclusion. → Learn more
MED's change over the last 5 trading days is -0.1%, and over the last 1 trading day is -2.5%. Both are backward-looking price-change figures, not a forecast of future movement.
MED's current price is 4.0% below its 20-day high. This gap to the recent high is often watched as a proxy for nearby resistance. On this measure it currently falls in the 'near resistance' category. This reading is specific to MED on this scan date and can change quickly. → Learn more
MED's ATR% currently reads 2.8%, a 'daily range' level. This is a running measure of how much the price typically moves in a single session. Treat this as one data point on MED, not a standalone signal. → Learn more
MED's 20-trading-day relative strength versus SPY (S&P 500 ETF) is -1.0%. MED underperformed the S&P 500 over this particular window. Treat this as one data point on MED, not a standalone signal. → Learn more
No significant edge was measured for Bollinger Band Squeeze: 22.5% versus a 24.7% base rate across 7328 cases. Treat this as one data point on MED, not a standalone signal. → Bollinger Band Squeeze
Stocks holding ADX Trend Strengthening reached +15% 24.5% of the time, versus a 24.7% base rate — not a statistically significant difference (11420 cases). Treat this as one data point on MED, not a standalone signal. → ADX Trend Strengthening
Measured (n=12815), the hit-rate for +DI Dominance (24.6%) was not statistically distinguishable from the base rate (24.7%). Treat this as one data point on MED, not a standalone signal. → +DI Dominance
No significant edge was measured for Weekly Squeeze: 22.3% versus a 24.7% base rate across 8568 cases. As with any single metric, weigh this alongside MED's full indicator set. → Weekly Squeeze
Limitations of this page — Automatically calculated, not a stock recommendation. Score is a count of conditions met, not a prediction; base rates are historical measurements only (MED diagnostic as of 2026.10.24 11:10).
A history of past monitoring candidates — not investment advice. See the scanner's full track record here.